Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2019

View Archived Issues

Cyclacel Pharmaceuticals initiates phase I study of CYC-065 plus venetoclax in patients with CLL

Motor protein myosin drives metastasis

Protein links sleep and sickness

SGL-5213 demonstrates efficacy in preclinical model of impaired glucose tolerance

Novel GPR40 superagonist demonstrates remarkable preclinical efficacy in models of diabetes

Preclinical data presented on PBK-001 vaccine for the treatment of melioidosis

Tripartite motif family-like 2 downregulation reduces oral squamous cell carcinoma growth

CSIC patents new PDE8A inhibitors

FDA issues complete response letter for ALKS-5461 NDA for adjunctive treatment of MDD

GenSight announces 48-week data from RESCUE trial of GS-010 in LHON

Dart NeuroScience discloses PDE7B inhibitors

Oxford University signs option agreement with Blue Water Vaccines for universal influenza vaccine

Roche and Genentech identify RIP-1 inhibitors

Nerviano Medical Sciences synthesizes choline kinase inhibitors

Medshine Discovery presents Rho kinase inhibitors

Phosphorylation study gives insights into Chlamydia

OncoSec updates clinical progress with Tavo

Moderna exercises option for exclusive licensing agreement with Avacta

Tinagl1 protein may be therapeutic in triple-negative breast cancer

Circulating miR-3659 found useful for diagnosing dyslipidemia in patients with obesity

FDA clears IND for phase I/IIa trial of VLPM-01 malaria vaccine

BREEZE-AD1 and AD2 studies of baricitinib in atopic dermatitis meet primary endpoints

Eisai plans single phase III confirmatory study of BAN-2401 in early Alzheimer's

Biohaven plans to advance BHV-3500 into phase II for acute treatment of migraine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...